Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)
Phase 3
- Conditions
- Eldery patients with advanced squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000019843
- Lead Sponsor
- ational Hospital Organization Nagoya Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) symptomatic central nervous system metastases 2) A past hypersensitive for polysorbate or albmin 3) peripheral neuropathy CTCAE Grade 2 or more 4) uncontrolled pericardial or pleural effusion or ascites 5) prior palliative radiotherapy for metastatic lesion within 14 days before registration 6) Synchronous or metachronous active double malignancies 7) Infectious disease requiring systemic treatment or severe complications 8) do not consent to contraception 9) Positive for HBs antigen 10) positive for HBs antibody or HBc antibody, and positive for HBV-DNA 11) patients who have been judged by the invedtigator to be inappropriate in this clinical trial for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression-free survival, response rate, toxicity, quality of life